SCHEMBL6344619

SCHEMBL6344619

Cc1ccc(-n2nc(C)c3c(Cl)c4cccc(C)c4nc32)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
HSP90AB1 P08238 1/20 0.35
NR3C1 P04150 5/20 0.34
KMT2A Q03164 4/20 0.33
MAPK1 P28482 1/20 0.33
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
GAA P10253 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 2/20 0.32
RAD52 P43351 1/20 0.32
ALDH1A1 P00352 1/20 0.32
BLM P54132 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
P2RX7 Q99572 1/20 0.31
TNKS O95271 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6352110 0.86 KDM4E (0.41) KDM4EHPGDHSP90AB1KMT2ACCNA2
SCHEMBL6341358 0.85 KDM4E (0.41) KDM4EHPGDHSD17B10KMT2ACCNA2
SCHEMBL6344026 0.83 KDM4E (0.43) KDM4EHPGDHSD17B10NR3C1KMT2A
SCHEMBL6342644 0.81 KDM4E (0.38) KDM4EHPGDHSD17B10NR3C1KMT2A
SCHEMBL6350556 0.79 KDM4E (0.38) KDM4EHPGDHSD17B10NR3C1KMT2A
SCHEMBL6343129 0.78 CCNA2 (0.38) KDM4EHPGDHSD17B10KMT2ACCNA2
SCHEMBL6339835 0.78 KDM4E (0.37) KDM4EHPGDHSD17B10HSP90AB1NR3C1
SCHEMBL5468508 0.76 NPC1 (0.38) KDM4EHPGDHSD17B10HSP90AB1NR3C1
SCHEMBL6342708 0.74 KDM4E (0.43) KDM4EHPGDHSD17B10NR3C1KMT2A
SCHEMBL6340357 0.74 ALDH1A1 (0.40) KDM4EHPGDHSD17B10KMT2ACCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949648-B2 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-27 US disclosed
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1270572-A1 CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof PTGS1, PTGIS, IL5 KDM4E 1741/4885HPGD 19/4885HSD17B10 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.